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esponsibility of Xi’Abstract A simple, eco-friendly, sensitive and economic ﬂow injection spectroﬂuorimetric method was
developed for the determination of O-(β-hydroxyethyl)rutosides. The procedure was based on the use of
an anionic surfactant such as sodium dodecyl sulfate to provide an appreciable O-(β-hydroxyethyl)
rutosides ﬂuorescence enhancement, increasing considerably the sensitivity of detection. All the variables
affecting the ﬂuorescence intensity were studied and optimized. The ﬂow rate was 5 mL/min with
detection at 450 nm (after excitation at 346 nm). A linear correlation between drug amount and peak area
was established for O-(β-hydroxyethyl)rutosides in the range of 0.01–200 mg/mL with a detection limit of
0.001 mg/mL (s/n¼3). Validation processes were performed by recovering studies with satisfactory
results. The new methodology can be employed for the routine analysis of O-(β-hydroxyethyl)rutosides in
bulks as well as in commercial formulations.
& 2014 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Hydroxyethylrutosides (Fig. 1, oxerutins, O-β-hydroxyethyl-ruto-
sides, HR) are hydroxyethyl acetylations of rutoside, semisynthetic
derivatives of Sophora japonica L. (Leguminosae), a well-known
traditional Chinese medicinal herb, ofﬁcially listed in the Chinesesity. Production and hosting by Else
2
ímica de San Luis (INQUISAL-
el.: þ54 2664 446765.
C.M. Peralta).
an Jiaotong University.Pharmacopoeia [1]. Its buds and fruits have been used as hemo-
static agent in traditional Chinese medicine. Pharmacological
studies and clinical practice have demonstrated that S. japonica
L. has anti-tumour, anti-fertility and anti-cancer activities [2,3] and
the active constituents of the herb are ﬂavonoid components. The
ﬂavones from its buds and pericarps were discovered as hemostatic
constituents [4,5].
HR has been used in the treatment of varicose veins and
other disorders as hemorrhoids which cause blood to pool. It is
in a class of medications known as ﬂavonoids and works by
repairing damage to capillaries and making them less susceptiblevier B.V. All rights reserved.
Fig. 1 Chemical structure of troxerutin.
O-(β-hydroxyethyl)rutosides determination 369to subsequent damage. HR helps to stabilize cell walls, making
them less permeable, so that ﬂuids are passed between cells and
blood cells at normal levels. This prevents blood from pooling in
the veins, which is the main cause and symptom of the varicose
vein disorder.Table 1 Methods for HR determination.
Instrumental
methodology
Comments
TLC The inclusion capacity of cyclodextrins follows the o
CD4M-β-CD4β-CD4γ-CD. Rutin is more easily in
studied cyclodextrins than venoruton. Other experime
pH¼9.7, 20 1C.
Circular dichroism After oral administration of 4 g HR the blood concen
Venoruton has a maximum between 6 and 10 h and t
detected by circular dichroism up to 25 h in blood. H
evaluation of the data for pharmacokinetics is not poss
Spectroﬂuorimetry The method is based on the ﬂuorescence behavior of
HR–aluminum complex in absolute methanol; λex/em¼
HPLC-UV and
ﬂuorescence
detection
A microcolumn of Amberlite XAD-2 is used to preco
before the injection in LiChrosorb RP-8 column using
(λex/em¼355/460 nm).
HPLC-diode array
detection
Reversed-phase HPLC is use for the determination of
active plant phenolic compounds mangiferin, likviritin
dihydroquercetin. Other experimental conditions: C18
290 nm.
HPLC-UV
detection
Quercetin was evaluated by HPLC using kaempferol
standard; Other experimental conditions: C18 column
rate: 1.0 mL/min; 375 nm.
HPLC-
electrochemical
detection
MonoHER was analyzed by HPLC, using a reversed-
column, with a mobile phase consisting of 49% metha
an aqueous solution containing 10 mM sodium dihyd
(pH 3.4), 10 mM acetic acid and 36 mM EDTA.
This work Flow injection spectroﬂuorimetric method is used for
determinations. Experimental conditions: λex/em¼346/
SDS: 20 mM; ﬂow rate: 5 mL/min; sampling rate: 30
LOD: Limit of detection, LOL: Limit of lineality, RSD: Relative standard de
hydroxypropyl-β-cyclodextrin, M-β-CD: methyl-β-cyclodextrin, HPLC: H
7-monohydroxyethyl rutoside, WD: without datum.A number of methodologies have been developed to determine
unlabeled HR and their metabolites (Table 1) such as TLC,
circular dichroism, and spectroﬂuorimetry [6–8]. More reliable
HPLC with UV, diode array detection or ﬂuorescence detection
methods were developed to monitoring different ﬂavonoids in
various body ﬂuids of humans and animals [9–11]. More recently,
HPLC with electrochemical detection was used for the deter-
mination of 7-monohydroxyethylrutoside in plasma [12]. British,
European and US Pharmacopoeias [13–15] do not have a method
for determining HR in raw drug or pharmaceuticals.
The ﬂow injection (FI) technique is very useful for the rapid
determination of many samples because it can accomplish high
sampling automatism with good precision. Moreover, an ideal
analytical method for routine analysis and quality assurance should
be simple, cost-effective, robust, precise and accurate, and have a
high sample analysis frequency [16,17]. These automatic techni-
ques offer signiﬁcant advantages for the determination and the
monitorship of one analyte (e.g. the active ingredient) and there-
fore can be applied to routine analysis.
The purpose of this work is to develop an alternative FI spectro-
ﬂuorimetric methodology for the determination of total oxerutins in
pharmaceuticals. The loss of sensitivity produced in ﬂow-injection
systems by dispersing the analyte into the carrier can be saved using a
molecular ﬂuorescence as a detector; additionally, a beneﬁcial enhance-
ment of natural analyte emission can be produced by micellar media.LOD LOL RSD Samples Ref.
rder HP-β-
cluded by the
ntal conditions:
WD WD WD Pure drug [6]
tration of
he drug can be
owever,
ible. λ¼345 nm.
WD WD WD Serum and
urine
[7]
the
420/480 nm.
WD 0.1–
4.0 mg/
mL
1.34 Urine [8]
ncentrating HR
solvent gradient
1 mg/L WD 8 Serum [9]
the biologically
and
column;
0.2/
0.5 mg/
mL
0.5–
20 mg/
mL
3.8 Rat plasma
and urine
[10]
as internal
; pH 3.5; ﬂow-
0.1 mg/
mL
300 nM–
3 mM
9.9 Human
plasma
[11]
phase ODS
nol and 51% of
rogen phosphate
WD 0.3–
75 mM
19.5 Plasma [12]
HR
450 nm; pH 9.0;
samples/h.
0.001 mg/
mL
0.01–
200 mg/
mL
4.86 Pharmaceuticals
viation, TLC: Thin layer chromatography, CD: cyclodextrin, HP-β-CD:
igh-performance liquid chromatography, UV: ultraviolet, MonoHER:
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2.1. Apparatus
All ﬂuorescent measurements were carried out on a Shimadzu
RF-5301PC spectroﬂuorometer (Shimadzu, Analytical Instrument
Division, Kyoto, Japan), equipped with an Xenon discharge lamp
and 1 cm quartz cells. For ﬂow measurements, an LC ﬂow cell unit
(12 μL cell) was used. The ﬂuorescent emissions were measured at
λem 450 nm, using a λexc 346 nm. An injection valve (Rheodyne
Model 5041) was used for FIA conﬁguration. Solutions were
propelled by a peristaltic pump (Gilson Minipuls 3) with pumping
tubes. All tubes connecting the different components of the ﬂow
system were PVC, 0.8 mm i.d. All pH measurements were made
with a pH meter (Model EA 940, Orion Expandable Ion Analyzer,
Orion Research, Cambridge, MA, USA) with combined glass
electrode.2.2. Reagents
O-β-hydroxyethylrutosides was purchased from Lab. Novartis (Buenos
Aires, Argentina). Sodium dodecyl sulphate (SDS) and hexadecyltri-
methylammonium bromide (HTAB) were obtained from Tokyo Kasei
Industries (Chuo-Ku, Tokyo, Japan). Triton X-100 (TX-100) was
purchased from Merck (Darmstadt, Germany).2.3. Preparation of standard solutions and samples
Standard solutions: HR standard solution containing 0.1 mg/mL
was prepared by dissolving the reagent in water. Under these
conditions, HR solution was found to be stable for several weeks
when kept in dark. A standard working solution of 10 μg/mL was
prepared daily by dilution of stock standard solution with dually
distilled water and stored in a dark bottle. SDS solution (20 mM)
and basic solution (20 mM borax) were prepared in dually distilled
water.
Sample: Five capsules of Venorutóns (Lab. Novartis, Bs. As.,
Argentina) or ﬁve tablets of Veraldids (Soubeiran Chobet, Bs.
As., Argentina) were weighed (to obtain the average mass of
tablets) and ﬁnely powdered. A portion of the powder, equivalent
to 300 mg of HR (one capsule) or 250 mg (one tablet), was
accurately weighed and dissolved in 80 mL of bidistilled water and
ﬁltered to remove insoluble material. The ﬁltered solution was
transferred to a 100 mL volumetric ﬂask and completed to the
volume with dually distilled water. The ﬁnal concentration was
about 3 or 2.5 mg/mL of HR. A solution of 0.1 mg/mL was
prepared by dilution of the sample solution with bidistilled water.
Further dilutions were done daily with bidistilled water.Sample
PP
Manual 
Valve1
2
SDS/Buffer
Fig. 2 FIA conﬁguration. PP: PerA portion of Venorutóns gel, equivalent to 50 mg of HR, was
accurately weighed and dissolved in 40 mL of bidistilled water and
ﬁltered to remove insoluble material. The ﬁltered solution was
transferred to a 50 mL volumetric ﬂask and completed to the
volume with bidistilled water. The ﬁnal concentration was about
1 mg/mL of HR. A solution of 0.1 mg/mL was prepared by dilu-
tion of the sample solution with bidistilled water. Further dilutions
were done daily with bidistilled water.
2.4. General procedure
A stream of sample or standard solutions containing HR was
combined with the carrier stream prepared with SDS (20 mM) and
buffer sodium tetraborate (pH 9) to obtain the optimal conditions
for analyte ﬂuorescent emission (Fig. 2). The drug contained in the
sample or standards and the carrier stream interacted in the mixed
coil (MC) and ﬂowed to the ﬂuorescence detector. The manual
valve was switched in such a manner that allowed, in one position,
to pass the carrier stream to the detector to generate the blank
signal, and in the second position allowed to pass the sample/
standards and carrier solution.
2.5. Validation procedure
In order to demonstrate the validity of this methodology, an
accurate weight of commercial tablets (Veraldids) powder con-
taining 250 mg of HR was dissolved and transferred to a 100 mL
volumetric ﬂask and completed to the volume with water. A por-
tion of 4 mL of this sample solution was transferred to 10 volu-
metric ﬂasks of 10 mL. The general procedure was applied to six
portions and the average quantity of HR determined was taken as a
base value. Then, increasing quantities of HR were added to other
four aliquots of sample and HR concentrations were determined by
applying the addition standard method.
The same validation procedure was applied for Venorutóns
capsules and gels.3. Results and discussion
3.1. Fluorescence characteristics of HR in aqueous and micellar
media
In order to study the spectral behavior of HR, systems were
prepared containing aqueous solutions and micellar solutions of
drug: anionic (SDS 0–20 mM), cationic (HTAB 0.9–9 mM) and
non-ionic (TX-100 0.05–0.1 M). In aqueous solution, HR showed
a ﬂuorescent emission at 468 nm when excited at 346 nm (Fig. 3).
In HTAB and TX-100 solutions, HR did not present beneﬁcialWaste
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1
2
MC
istaltic pump. MC: Mixed coil.
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Fig. 3 Excitation and emission ﬂuorescence spectra for HR. (a, b) HR
in aqueous solutions; (c, d) in SDS micellar media. CHR¼5 mg/mL;
CSDS¼20 mM. λexc¼346 nm; λem¼450 nm.
Fig. 4 Determination of experimental CMC value for HR–SDS
system. CHR¼5 mg/mL. CSDS¼0–20 mM. λexc¼346 nm; λem¼450
nm. CMC value obtained: 0.57 mM.
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Fig. 5 Effect of pH on HR ﬂuorescence intensity. CHR¼5 mg/mL;
CSDS¼20 mM; λexc¼346 nm; λem¼450 nm.
O-(β-hydroxyethyl)rutosides determination 371changes in emission signals. When SDS micellar medium was
used, a hypsochromic shift and a beneﬁcial intensity increase were
observed with a maximum of emission at 450 nm when excited at
346 nm. Experimental data showed an enhancement factor for the
HR–SDS system of 4-fold with respect to HR ﬂuorescence in
water medium; thus, the anionic surfactant SDS was chosen for
further analysis, at a concentration of 20 mM. Likewise, these
wavelengths for HR–SDS system (λem¼450 nm; λexc¼346 nm)
were selected to measure the ﬂuorescence intensity for the sub-
sequent assays.
With the aim of establishing the optimal SDS concentration
allowing the best increase in HR ﬂuorescent signal, experiments
were performed by varying SDS concentration and maintaining
constant other experimental conditions. The results obtained
(Fig. 4) have highlighted that the CMC value of SDS has been
diminished by the presence of HR, giving a value of 0.57 mM,
being less than for the SDS solution [18].3.2. Inﬂuence of several experimental variables
Fig. 5 depicts the effect of pH value on the ﬂuorescence signal for
HR. Analysis of spectroﬂuorimetric data for HR in SDS micellarsolutions showed a maximal intensity in the pH range of 3–10 and
a decrease to extremely acidic or alkaline pH. The working pH
selected was 9, using sodium tetraborate as the buffer solution.
The effect of the concentration of the buffer solution was studied.
Fluorescence intensity remained constant in the maximum emis-
sion for buffer concentrations from 1 mM to 20 mM; higher
concentrations led to a ﬂuorescence decay. In order to maintain
pH value in a constant optimal value, a concentration of 20 mM
was selected and used in the following assays.
3.3. FI system optimization
Several experiments were done in order to study the effect of the
length of the mixed coil and the ﬂow rate of the FI system on the
HR ﬂuorescent signal. The presence of the mixed coil in the FIA
manifold ensures adequate a mixture of SDS and the HR sample
due to convective forces in play, guaranteeing the arrival to the
detector of a homogeneous composition. The mixed coil length
was evaluated in order to obtain the HR highest signal from 5 to
15 cm. The best results were obtained using an MC of 10 cm.
Then, experiments were realized by varying the ﬂow rate. The
results showed that the ﬂuorescent signal increased with the
increase of ﬂow rate. For rates 4 5 mL/min great turbulence
was observed, due to the presence of SDS surfactant and the
introduction of bubbles into the FI system, with consequent
ﬂuctuation in the ﬂuorescent values. A ﬂow rate of 5 mL/min
was selected as optimal. Under these optimal conditions the
sampling rate was 30 samples/h.
3.4. Analytical performance and validation
3.4.1. Linearity
The equation for the calibration graph was obtained by least-
squares regression analysis, employing the areas of the analyte
standard ﬂuorescent signals: F¼0.6143Cþ6.68, where F is the
relative ﬂuorescence intensity and C is the concentration of HR.
The method was linear in the range of 0.01–200 μg/mL HR. The
correlation coefﬁcient (r2) was 0.9959. The ﬁgures of merit obtained
demonstrated the good performance of the calibration.
3.4.2. Limit of detection and limit of quantiﬁcation
The limit of detection (LOD) was deﬁned as the compound
concentration that produced a signal:noise (s/n) ratio 43, while
the limit of quantiﬁcation (LOQ) of the assay was evaluated as the
concentration equal to 10 times the value of the s/n ratio [19].
LOD and LOQ values for this method, based upon these criteria,
were 0.001 and 0.01 μg/mL, respectively.
Table 2 Validation of the proposed method for HR determination in commercial pharmaceutical formulae.
Sample Added μg/mL) Within-day Between-day
Founda Recoveryb (%) RSD (%) Founda Recoveryb (%) RSD (%)
Veraldid® – 0.13 – – 0.14 – –
tablets 0.1 0.21 110.00 4.75 0.19 92.10 4.86
0.2 0.29 99.05 4.43 0.32 110.00 4.09
0.4 0.52 105.08 3.90 0.53 109.96 3.89
– 1.09 – – 1.13 – –
Venorutón® 1 2.07 107.99 3.21 2.10 110.00 3.87
capsules 2 2.91 95.51 3.98 3.02 101.15 3.63
4 5.11 102.75 2.81 5.16 104.02 2.98
8 8.88 98.52 2.42 8.76 97.89 3.08
Venorutón® – 10.98 – – 9.54 – –
gel 10 19.82 98.20 2.38 21.00 110.00 3.67
20 31.99 109.95 1.53 28.66 93.39 3.53
40 48.67 96.68 2.02 48.59 96.47 3.31
80 90.35 100.44 1.26 87.62 97.02 2.94
aMean value, n = 6.
bRecovery = [(found−base)/added] ×100.
Table 3 Analysis of HR in pharmaceutical samples by the
developed spectroﬂuorimetric method (n¼6).
Samplea HR nominal quantity HR found Ec (%)
Capsulesa 300 mg 309.85 mg 3.28
Gela 2 g per 100 g 2.2 g 9.12
Tabletsb 250 mg 236.99 mg 5.20
aVenorutóns (Novartis, Bs. As., Argentina).
bVeraldids (Soubeiran Chobet, Bs. As., Argentina), HR content
250 mg, and 150 mg of magnesium ascorbate.
cPercentual relative error (calculated considering that the pre-
parations contain the amount reported by the manufacturing
laboratories).
C.M. Peralta, L.P. Fernández3723.4.3. Reproducibility
The ﬁagram was registered for different standards of HR: (a) 2 μg/mL;
(b) 3 μg/mL; (c) 4 μg/mL; (d) 6 μg/mL; and (e) 8 μg/mL. The tripli-
cate signals demonstrated good reproducibility for the developed
methodology.
3.4.4. Accuracy and precision
The within-day and between-day precisions of the method, based
on repeatability, were determined by replicating injections (n¼6)
on ﬁve sample solutions of different commercial formulations pre-
pared by the standard addition method at different concentration
levels. A relative standard deviation (RSD) r4.86% was obtained
in all cases. The within-day and between-day recoveries were in
the range of 92.10–110.00% (Table 2).
3.4.5. Speciﬁcity
The presence of other active drugs with which pharmaceuticals
containing HR can be formulated (such as magnesium ascorbate),
or of the common excipients of the analyzed formulations, was
observed not to cause spectral interferences. This is an important
advantage of the method, since it allows for the analysis of HR
without a prior separation step.
3.4.6. Robustness
This was evaluated by challenging each operational parameter of
the proposed method such as concentration of SDS, pH and ﬂow
rate. It was found that none of these variables signiﬁcantly affected
the analytical parameters of the method. This provides an
indication of the reliability of the proposed method during normal
usage, and so it can be considered robust.
3.5. Applications: determination of HR in pharmaceuticals
To assess the utility of the proposed method, several pharmaceu-
tical preparations in different physical forms were analyzed byapplying the general procedure. Results are included in Table 3.
All values were in good agreement with the nominal values.
4. Conclusions
Taking into account the characteristics of the FI-spectroﬂuorimetry
used in this work, the proposed methodology for the determi-
nation of HR is more simple, sensitive and rapid than the
procedures previously reported. A sampling rate of 30 samples/h
was attained, without including the pretreatment sample time.
The use of SDS micellar system provides a simple means to
enhance the ﬂuorescence from HR giving about 4-fold increase
in sensitivity and improves the limit of detection without further
sample manipulation. The proposed method shows good accuracy
and reproducibility, compared with the other methods described
(see Table 1) and has been applied to the determination of HR in
pharmaceuticals, since there is no interference from excipients or
additives that might be found in different commercial formula-
tions. Due to the small volumes of sample and reagents employed
and their nontoxic characteristics, this method contributes to a
clean or environmentally friendly analytical chemistry.
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